Company Overview and News

0
Analysts see tough days ahead for housing finance companies

2018-06-08 thehindubusinessline
Our Bureau Share prices of housing finance companies will remain under pressure on margin concerns due to rising bond yields, say analysts.
GRUH GICHSGFIN DHFL 511072 LICHSGFIN GRHFY 535322 LHFLY 511676 500253 511288 REPCOHOME

0
GIC Housing Finance Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GICHSGFIN 511676

0
GIC Housing Finance Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-04-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GICHSGFIN 511676

0
GIC Housing Finance Limited - Clarification - Financial Results

2018-04-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GICHSGFIN 511676

34
Market Live: Sensex dips over 150 pts, Nifty breaks 10,550; rupee falls to 66.80/$, Europe down

2018-04-25 moneycontrol
2:40 pm Rupee Update: The Indian rupee extended fall to 66.80 against the US dollar, down 42 paise from previous closing of 66.38 a dollar on bouts of month-end dollar demand from importers amid crude price volatility and rising US bond yields.
500249 JIPKY ICLQY 511389 532832 533179 532960 5225 534816 UCLQY 509220 SBAZ GICHSGFIN ATFL SYNGENE 500215 VOD 532508 539268 STRTECH 511676 532822 ULTRACEMCO SRLRY 500182 FORTIS 500180 KSBPUMPS Q0F PTL IBREALEST BHRYY 512573 532538 BHRQY VIDEOIND IDBLZ 532187 INFRATEL HDFCBANK HEROMOTOCO JSL BHARTIARTL IHHHF AVANTI VOD INDUSINDBK IBVENTURES IBN UCLQF JPASSOCIAT 532843 532532 532454 ICICIBANK 532374 VODPF HDB 532174 IDEA HRTQY PERSISTENT

0
GIC Housing Finance Limited - Updates

2018-04-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GICHSGFIN 511676

0
GIC Housing Finance Limited - Financial Result Updates

2018-04-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GICHSGFIN 511676

0
GIC Housing Finance Q4 profit up 28% at Rs60 crore

2018-04-24 livemint
New Delhi: GIC Housing Finance on Tuesday reported a rise of 28% in net profit at Rs59.87 crore for the last quarter of 2017-18 financial year ended 31 March.
GICHSGFIN 511676

0
GIC Housing Finance Limited - Outcome of Board Meeting

2018-04-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GICHSGFIN 511676

0
GIC Housing Finance Limited - Dividend

2018-04-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GICHSGFIN 511676

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...